Evidence map›Paper›PMID 41586257›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2025

Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications.

Saumya Nishanga Heendeniya, Suxiang Chen, Saadia Bhatti, Qurat Ul Ain Zahra, Kamal Rahimizadeh, Bal Hari Poudel, Stephen D Wilton, Rakesh N Veedu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saumya Nishanga HeendeniyaPersonalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.
Suxiang ChenPersonalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.
Saadia BhattiPersonalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.
Qurat Ul Ain ZahraPersonalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.
Kamal RahimizadehPersonalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.
Bal Hari PoudelPersonalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.
Stephen D WiltonPersonalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.
Rakesh N VeeduPersonalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Messenger RNA (mRNA) therapeutics have significantly transformed contemporary medicine, particularly through their role as the active component in the SARS-CoV-2 vaccine. This remarkable achievement is the culmination of extensive research conducted over many years by scientists. The widespread administration of the COVID-19 vaccine has further accelerated research into the precise therapeutic potential of mRNA technologies. Since mRNA doesn't integrate with the host genome, the safety and versatility of mRNA-based therapeutics make them an iconic candidate in targeted therapies. Due to a surge in innovation efforts, biomodification of the molecular signatures of mRNAs like the 5'cap, untranslated regions (UTRs), and the poly(A) tail are being developed to increase translation efficacy. Recent advancements in chemical modifications, codon optimization techniques, and targeted delivery methods have significantly enhanced the stability of synthetic mRNAs while concurrently reducing their immunogenicity. Various mRNA manufacturing and synthesizing methods are investigated in this review, focusing on their scalability and limitations. mRNA therapeutic strategies can be divided into protein replacement, immune modulation, and cellular modulation. This review explores mRNA's molecular landscape and comprehensive utility, including applications in both clinical trials and commercial sectors.

Indexed as

COVID-19 VaccinesDrug DesignRNA, MessengerSARS-CoV-2AnimalsCOVID-19HumansCOVID-19 VaccinesRNA, MessengermRNA deliverymRNA design and synthesismRNA patents and clinical trialsmRNA therapeuticsmRNA vaccineprotein replacement therapy

Identifiers

PMID41586257
PMCPMC12824530

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.